Cell And Gene Therapy Clinical Trial Services Market Report: Global Size, Share, Trends, Opportunities And Forecast 2033

Overview and Scope

Cell and gene therapy clinical trial services refer to specialized services offered by contract research organizations (CROs) or clinical trial management corporations to facilitate the design, implementation, and management of clinical trials for cell and gene therapies. These services, which range from protocol design and patient recruiting to regulatory compliance and data administration, serve as the foundation for trials to progress smoothly, ensuring precision, efficacy, and adherence to high standards.

Sizing and Forecast

The cell and gene therapy clinical trial services market size has grown rapidly in recent years. It will grow from $3.44 billion in 2023 to $3.79 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to the increased prevalence of chronic diseases, increased demand for effective treatments for rare genetic disorders, increased government funding for research in regenerative medicine, increased understanding of molecular mechanisms underlying various diseases, and increased awareness of the potential of personalized medicine.

The cell and gene therapy clinical trial services market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing global incidence of genetic and auto-immune diseases, rising public and private sector funding for gene therapy research, growing adoption of novel technologies, and a rise in the number of genetic defects. Major trends in the forecast period include the adoption of AI, the adoption of machine learning, the adoption of personalized medicine, technological advancements, and gene therapies.

Order your report now for swift delivery, visit the link:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Segmentation & Regional Insights

The cell and gene therapy clinical trial services market covered in this report is segmented –
1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

North America was the largest region in the cell and gene therapy clinical trial services market in 2023. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

Major Driver Impacting Market Growth

The rising incidence of genetic disease is expected to propel the growth of the cell and gene therapy clinical trial services market going forward. Genetic diseases are ailments caused by variations in a person's DNA or genetic composition. The incidence of genetic diseases is on the rise due to numerous factors, including the increased availability of genetic testing, the occurrence of genetic mutations, and the prevalence of consanguineous marriage. Cell and gene therapy clinical trial services address the rising incidence of genetic diseases by encouraging the development of novel treatments, tailoring therapies to individual patients, accelerating the translation of research into clinical practice, and expanding the options available to patients suffering from genetic disorders. For instance, in July 2022, according to the Cystic Fibrosis (CF) Foundation, a US-based non-profit organization, there had been an upsurge in the number of people with cystic fibrosis. In 2022, cystic fibrosis affected almost 40,000 children and adults in the United States, and over 105,000 people worldwide have been diagnosed. Therefore, the rising incidence of genetic disease is driving the growth of the cell and gene therapy clinical trial services market.

Key Industry Players

Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

The cell and gene therapy clinical trial services market report table of contents includes:
1. Executive Summary

2. Market Characteristics

3. Market Trends And Strategies

4. Impact Of COVID-19

5. Market Size And Growth

6. Segmentation

7. Regional And Country Analysis

…………

27. Competitive Landscape And Company Profiles

28. Key Mergers And Acquisitions

29. Future Outlook and Potential Analysis

Contact Us:

The Business Research Company

Europe: +44 207 1930 708